Bayer AG, the multinational pharmaceutical company, has been navigating through diverging paths in pharma strength and agriculture challenges. Its stock has experienced a surge, with a 70% one-year share price increase, but also periods of decline, with a 1.9% drop recorded. Factors contributing to shifts include the company's profit guidance falling short of expectations and the pursuit from activist investor Inclusive Capital to sell their stake in Bayer. Despite this turbulence, boosts have been seen from FDA approval for expanded MR injector application and positive FIND-CKD results for the renal drug Kerendia. Analysts also react to Bayer's $7.25bn litigation offer and Q4 loss with various outlooks. There was a considerable slump in the stock after unveiling plans for Roundup settlement, countered however by surges following the partnership forecast with Deere and positive Nubeqa outlook. The Supreme Court agreeing to review the Roundup case has also been influential, pushing shares upwards. On the innovation front, the company plans to accelerate growth with siRNA, AI deals, and pipeline progress.
BAYER Stocks News Analytics from Tue, 11 Nov 2025 08:00:00 GMT to Sat, 28 Mar 2026 12:20:24 GMT -
Rating 2
- Innovation 7
- Information 6
- Rumor -2
